Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann H Partridge

Showing results (291-300 of 363) with videos related to

Pageof 37
Sort By:
JCO Precision Oncology|June 26, 2023
Genomics of <i>ERBB2</i>-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus TrastuzumabMarla Lipsyc-Sharf, Esha Jain, Laura C Collins, et al.
JAMA Oncology|September 4, 2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical TrialSara M Tolaney, Romualdo Barroso-Sousa, Tanya Keenan, et al.
JAMA Network Open|September 23, 2022
Contraceptive Use in Premenopausal Women With Early Breast CancerMatteo Lambertini, Claudia Massarotti, Julie Havas, et al.
Plos One|May 25, 2019
Evaluation of significant genome-wide association studies risk - SNPs in young breast cancer patientsMichelle Rath, Qiyuan Li, Huili Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2018
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level DataMatteo Lambertini, Halle C F Moore, Robert C F Leonard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort StudyCarmine Valenza, Yue Zheng, Monica Milano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2022
Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship CareAntonio Di Meglio, Julie Havas, Davide Soldato, et al.
Journal of the National Cancer Institute|May 5, 2022
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted TherapyMatteo Lambertini, Shona Fielding, Sibylle Loibl, et al.
The New England Journal of Medicine|January 8, 2015
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancerSara M Tolaney, William T Barry, Chau T Dang, et al.
Breast (Edinburgh, Scotland)|April 29, 2020
Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical studyAntonio Di Meglio, Stefan Michiels, Lee W Jones, et al.
Pageof 37

Showing results (291-300 of 363) with videos related to

Sort By:
Pageof 37
JCO Precision Oncology|June 26, 2023
Genomics of <i>ERBB2</i>-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus TrastuzumabMarla Lipsyc-Sharf, Esha Jain, Laura C Collins, et al.
JAMA Oncology|September 4, 2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical TrialSara M Tolaney, Romualdo Barroso-Sousa, Tanya Keenan, et al.
JAMA Network Open|September 23, 2022
Contraceptive Use in Premenopausal Women With Early Breast CancerMatteo Lambertini, Claudia Massarotti, Julie Havas, et al.
Plos One|May 25, 2019
Evaluation of significant genome-wide association studies risk - SNPs in young breast cancer patientsMichelle Rath, Qiyuan Li, Huili Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2018
Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level DataMatteo Lambertini, Halle C F Moore, Robert C F Leonard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort StudyCarmine Valenza, Yue Zheng, Monica Milano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2022
Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship CareAntonio Di Meglio, Julie Havas, Davide Soldato, et al.
Journal of the National Cancer Institute|May 5, 2022
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted TherapyMatteo Lambertini, Shona Fielding, Sibylle Loibl, et al.
The New England Journal of Medicine|January 8, 2015
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancerSara M Tolaney, William T Barry, Chau T Dang, et al.
Breast (Edinburgh, Scotland)|April 29, 2020
Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical studyAntonio Di Meglio, Stefan Michiels, Lee W Jones, et al.
Pageof 37